Literature DB >> 16985077

Intracellular expression of the T-cell factor-1 RNA aptamer as an intramer.

Kang Hyun Choi1, Min Woo Park, Seung Yeon Lee, Mi-Ya Jeon, Mee Young Kim, Hee Kyu Lee, Jaehoon Yu, Hong-Jin Kim, Kyungsook Han, Heviran Lee, Keerang Park, Woong June Park, Sunjoo Jeong.   

Abstract

T-cell factor (TCF)-1 protein forms the transcriptional complex with beta-catenin and regulates the expression of diverse target genes during early development and carcinogenesis. We have selected previously an RNA aptamer that binds to the DNA-binding domain of TCF-1 and have shown that it interfered with binding of TCF-1 to its specific DNA recognition sequences in vitro. As an approach to modulate the transcription by TCF/beta-catenin complex in the cells, we have developed the RNA expression vector for stable expression of RNA aptamer inside of the mammalian cells. High level of RNA was expressed as an intramer in the fusion with the stable RNA transcript. The RNA intramer inhibited TCF/beta-catenin transcription activity as shown by luciferase assay. It also modulated the expression of TCF/beta-catenin target genes, such as cyclin D1 and matrix metalloproteinase-7, as predicted to be as an effective inhibitor of the TCF function. In addition, it efficiently reduced the growth rate and tumorigenic potential of HCT116 colon cancer cells. Such RNA intramer could lead to valuable gene therapeutics for TCF/beta-catenin-mediated carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16985077     DOI: 10.1158/1535-7163.MCT-05-0204

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  10 in total

Review 1.  Recent advances in understanding oligonucleotide aptamers and their applications as therapeutic agents.

Authors:  Khaled S Allemailem; Ahmad Almatroudi; Mohammed A Alsahli; Ghaiyda Talal Basfar; Faris Alrumaihi; Arshad Husain Rahmani; Amjad Ali Khan
Journal:  3 Biotech       Date:  2020-11-24       Impact factor: 2.406

2.  Bioimaging of nucleolin aptamer-containing 5-(N-benzylcarboxyamide)-2'-deoxyuridine more capable of specific binding to targets in cancer cells.

Authors:  Kyue Yim Lee; Hyungu Kang; Sung Ho Ryu; Dong Soo Lee; Jung Hwan Lee; Soonhag Kim
Journal:  J Biomed Biotechnol       Date:  2010-03-01

3.  RNA aptamers and their therapeutic and diagnostic applications.

Authors:  Katherine Germer; Marissa Leonard; Xiaoting Zhang
Journal:  Int J Biochem Mol Biol       Date:  2013-03-31

Review 4.  Aptamers for allosteric regulation.

Authors:  Jan L Vinkenborg; Nora Karnowski; Michael Famulok
Journal:  Nat Chem Biol       Date:  2011-07-18       Impact factor: 15.040

5.  Blocking the maturation of OncomiRNAs using pri-miRNA-17∼92 aptamer in retinoblastoma.

Authors:  Nithya Subramanian; Jagat R Kanwar; Rupinder K Kanwar; Subramanian Krishnakumar
Journal:  Nucleic Acid Ther       Date:  2014-12-16       Impact factor: 5.486

6.  Selection and characterization of anti-NF-kappaB p65 RNA aptamers.

Authors:  Susan E Wurster; L James Maher
Journal:  RNA       Date:  2008-04-21       Impact factor: 4.942

Review 7.  Wnt/beta-catenin signaling and small molecule inhibitors.

Authors:  Andrey Voronkov; Stefan Krauss
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

8.  Cell-specific aptamers as emerging therapeutics.

Authors:  Cindy Meyer; Ulrich Hahn; Andrea Rentmeister
Journal:  J Nucleic Acids       Date:  2011-08-28

Review 9.  Nucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical Sensing.

Authors:  Ti-Hsuan Ku; Tiantian Zhang; Hua Luo; Tony M Yen; Ping-Wei Chen; Yuanyuan Han; Yu-Hwa Lo
Journal:  Sensors (Basel)       Date:  2015-07-06       Impact factor: 3.576

Review 10.  Roles of transcriptional factor 7 in production of inflammatory factors for lung diseases.

Authors:  Yichun Zhu; William Wang; Xiangdong Wang
Journal:  J Transl Med       Date:  2015-08-20       Impact factor: 5.531

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.